Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Tumor-derived Cell-membrane Coated NanoVaccine (TCC-NV) as personalized neoantigen immunotherapy to enhance efficacy of TNBC treatments

Award Number: K22CA307628
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 08/01/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2029

Group Awards By:

View Award Description

Tumor-derived Cell-membrane Coated NanoVaccine (TCC-NV) as personalized neoantigen immunotherapy to enhance efficacy of TNBC treatments - PROJECT ABSTRACT This proposal seeks to overcome critical limitations in personalized therapeutic strategies for triple-negative breast cancer (TNBC), an aggressive subtype marked by poor prognosis. We propose developing personalized cancer treatment, designed to stimulate antigen-presenting cells and induce robust, antigen-specific T cell responses against TNBC cells. We develop cost-effective Tumor-derived Cell-membrane Coated NanoVaccine (TCC-NV) armed with adjuvants, that bypass limitation of resource-intensive neoantigen prediction, prioritization, and validation process. Our proposed TCC-NV integrated with radiotherapy (RT) addresses the challenge of low mutation burden in TNBC that often limits personalized neoantigen-based treatments. This multifaceted approach leverages immune-competent mouse models that closely mimic human TNBC, focusing on the innate and adaptive immune system's role in anti-tumor responses. Specific Aims are: 1) Evaluate antitumor activity of TCC-NV in TNBC tumor models. 2) Investigate radiation impact on increasing neoepitope presentation and determine whether immune checkpoint inhibitors (ICI) therapy can synergize with TCC-NV to eradicate TNBC tumors. The TCC-NV platform's production simplicity facilitates clinical translation and increases the potential for future clinical success in personalized treatment of primary and metastatic TNBC. This mechanistic study is related to the mission of the NCI as it aims to contribute to closing the knowledge gap in understanding the role and function of neoantigen-based cancer vaccine therapy and to provide survival benefits for TNBC patients who urgently require more effective treatment strategies beyond traditional chemotherapy. Dr. Yazdimamaghani’ s career goals are to integrate research from nanomedicine, radiation biology, oncology, and immunology to launch a robust and successful research program by receiving a tenure track faculty position. By leading multidisciplinary research to push the boundaries of personalized cancer immunotherapy and mentoring the next generation of scientists in immunoengineering, he aims to build a successful career as an assistant professor. His vision is to establish a highly collaborative research team focused on unraveling the complex dynamics of immune cell-biomaterial-tissue interactions within the TME, driving the development of innovative immunotherapeutic strategies for effective disease treatment. The NCI Transition Career Development Award is a vital cornerstone for successfully launching his independent research laboratory. It provides essential support for developing expertise in grant writing, effective research management, communication skills, and fostering constructive collaborations. Closely collaborating with Dr. Charles Perou, a world-renowned expert in breast cancer genomics and molecular subtypes, and Dr. Benjamin Vincent, a specialist in cancer immunogenomics, ensures comprehensive expertise, support, and access to state-of-the-art resources for the proposed experiments. Both collaborators are affiliated with the UNC School of Medicine and the UNC Lineberger Comprehensive Cancer Center, fostering an ideal environment for advancing this research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $191,762 )
2026	2026	UNIVERSITY OF MISSOURI SYSTEM	300 W. 12TH STREET	ROLLA	MO	65409	PHELPS	USA	Cancer Research Manpower	000	1	7/27/2026	NEW	$191,762
														Subtotal = $191,762

Grand Total All Awards = $191,762

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Tumor-derived Cell-membrane Coated NanoVaccine (TCC-NV) as personalized neoantigen immunotherapy to enhance efficacy of TNBC treatments

Award Number: K22CA307628

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 08/01/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer